
IM PGY-2 | Postdoc-Scientist @SmidtHeart-@CedarsSinai | Former Research Scholar @ Cleveland Clinic @CCAD| FESC @escardio |
Los Angeles, CA
Joined May 2021
- Tweets177
- Following338
- Followers273
- Likes2K
Pinned Tweet
Grateful for the opportunity to contribute to the latest ISHLT Consensus Statement on antibodies and antibody-mediated rejection after heart transplantation, led by Dr. Jon Kobashigawa @SmidtHeart and Dr Andreas Zuckermann.
🫀In memory of Dr. @JigPatelMDPhD
Link to statement : doi.org/10.1016/j.healun.202…
15
1,546
Yosef Manla, MD, FESC retweeted
What's my take on VIP medicine?
Find out here, in my new NEJM Voices piece.
You can sign up for email alerts so you never miss a piece, and access is FREE (you don't need a subscription to NEJM)!
voices.nejm.org/doi/full/10.…
Honored to contribute to the @AST_info Fellows Task Force Report @amjtransplant on Recommendations to overcome barriers to transplant fellowship training in the US, led by Dr.Kobashigawa et al.
Link: doi.org/10.1016/j.ajt.2025.0…
The document included recommendations tailored around four areas of focus, including :
🔹Early and sustained exposure to transplant medicine
🔹Awareness through education
🔹Flexible fellowships and pathways to transplant
🔹Work–life resources
@SmidtHeart @KiranKhush1 @spinneymd @afzal_aasim @ssfarouk @shelleyhallmd @MKIttlesonMD @DeirdreSawinski @AnjanaPillaiMD @virmani_sar @KidneyPrince
Yosef Manla, MD, FESC retweeted
Consensus statement by Kobashigawa & Zuckermann et al. reviews evaluation/management of circulating #antibodies before & after #HeartTx, and antibody-mediated rejection. @SmidtHeart @ManlaYosef
🔗: jhltonline.org/article/S1053…
Last week I had the great opportunity to present our work @SmidtHeart on HLA antibody Class and outcomes of sensitized Heart Transplant patient at #WorldTransplantCongress in SF
#WTC2025
Grateful to my mentor Dr.Kobashigawa and the team for their support
#Transplanation #OrganDonation | @AST_info | @ttsorg |
Yosef Manla, MD, FESC retweeted
Don't let great research stall. With JCF Express: Court of Appeals you can submit your previously reviewed manuscript for an expedited editorial decision. No starting over. No wasted effort. Resubmit today
hfsa.org/jcf-express-court-a…
Presented this at #ISHLT2025: In our single-center study @SmidtHeart , pre- heart transplant sensitization & older donor age were associated with immediate presentation of severe PGD-LV ⚠️.
Immediate presentation = worse 30-day & 1-yr survival vs delayed presentation 📉.@ISHLT
Yosef Manla, MD, FESC retweeted
Does Time Matter in #PGD presentation? @ISHLT @ManlaYosef
➡️ Study shows worse outcomes in immediate vs. delayed presentation w/ ⬇️ survival at 30d & 1 yr
Presenting our case series on variable responses to daratumumab for pre-transplant desensitization in adult heart transplant candidates #ISHLT2025 @ISHLT @SmidtHeart #transplantimmunology
Excited to share our recent paper summarizing @HFSA global roundtable discussions on heart failure innovation.
Link: doi.org/10.36628/ijhf.2024.0…
Grateful for the mentorship of Dr. Bader & Dr. Vest @NutritionHF and the opportunity to collaborate with HF Societies & leaders 🇺🇸 🇨🇦 🇨🇴 🇪🇺 🇬🇧 🇮🇳 🇯🇵 🇰🇷 🇦🇪worldwide to explore regional challenges and exchange solutions!
1/🧵
@HFSA @escardio @CanHFSociety @hfai20 @kshf_official @SmidtHeart @CleClinicHVTI @MarkDrazner @GMCRosano @yuya_matsue @Team_M_T @drjegomez @AniqueDucharme @BSHeartFailure
2/🧵
🌍 Key themes identified:
• 📊 Lack of high-quality, region-specific HF registry data
• 🏥Balancing accessible care vs. centralized specialized care
• ✅ Need for HF care accreditation & coordination across delivery centers
• ⏱️ Improving prevention & timely diagnosis, especially in underserved communities
• 👥Advancing multidisciplinary team-based care
229
Yosef Manla, MD, FESC retweeted
New online! 🗒️Pleased to share that our State-of-the-Art Review on SSc associated cardiovascular disease is now published on @JScleroderma. Thank you @MarbanLab for the constant support.
@scleroderma @SmidtHeart @YaleIMed
journals.sagepub.com/eprint/…
Yosef Manla, MD, FESC retweeted
Excited to share that our paper “Macrophages Contribute to Cardiac Fibrosis and Diastolic Dysfunction in Systemic Sclerosis” is now on @JACCJournals🫀🔬. Thank you @MarbanLab for the mentorship and ongoing support.
@SmidtHeart @YaleIMed
jacc.org/doi/10.1016/j.jacbt…
I am excited to share our recent publication @TheJHLT, demonstrating how therapeutic plasma exchange improves survival in patients experiencing severe primary graft dysfunction after heart transplantation.
Link: doi.org/10.1016/j.healun.202…
Beyond grateful to my mentor, Dr.Kobashigawa, and the team @SmidtHeart for the support and guidance
Yosef Manla, MD, FESC retweeted
One of my unintended passions is now exploring: How do we make #cardioonc succeed, 1 program at a time?
@yosefmanla @DSadlerMD et al reveal building blocks needed to build a program & how to leverage your local strengths & gaps in care for success!
link.springer.com/article/10…
8/🧵
So happy to reconnect with You, Obada! Keep up the great work!
Replying to @obada_kholoki
Another highlight from the conference was reuniting with a great friend and my research mentor @ManlaYosef, whose contributions to the research surrounding Heart Failure continue to be profoundly impactful.
1
364
Presenting our findings on predictors of Ischemia reperfusion injury post heart transplant #AHA24 @SmidtHeart @CedarsSinaiMed
We found that: Optimal prioritization of HTx candidates on the waitlist and use of ATG induction therapy seem to protect against immediate ischemia reperfusion injury post-HTx
3
14
696
Yosef Manla, MD, FESC retweeted
Great #AHA2024 presentation from @CedarsCards Dr. Rashmi Jain: Highly sensitized patients treated with desensitization prior to HT had higher rates of AMR but comparable survival and CAV rates compared to general HT population. @SmidtHeart @ISHLT @MKIttlesonMD @LilySternMD
































